In another study of 60 patients with advanced NSCLC treated with chemotherapy, progressive disease was associated with more baseline Mo-MDSCs (HLA-DR−/low, CD14+), and a baseline number of Mo-MDSCs under the median was also associated with longer median PFS (9 vs. 3 months, p < 0.001) (79). Here, CD14 is linked to non-small cell lung carcinoma.